Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF Lifesciences, an established contract research organisation, aimed at combining the strengths of Partex’s advanced AI & data services technology and Althea’s screening services and compounds.

The immediate scope of this exciting partnership is to provide end-to-end services from AI- driven drug discovery to wet lab validations to accelerate drug development.

Dr. Gunjan Bhardwaj, CEO of Partex, expresses enthusiasm about this innovative collaboration, stating, “We have been following Althea for quite some time and this collaboration is a logical next step for both companies in driving innovation in drug discovery. It will allow us to further strengthen our product development in many ways, and it will drive more future innovations.”

The longer-term scope of this collaboration is to develop and operate a digital pharma platform in various therapeutic areas, such as women’s health, dermatology, gut health, anxiety, sleep disorders, and metabolic diseases, all focusing on traditional and plant-based medicines.

Dr. Manu Jaggi, CEO Althea DRF Lifesciences encapsulated this collaboration as “A transformative leap forward in accelerating drug discovery and development, merging cutting-edge AI technology with proven screening services to pave the way for groundbreaking innovations in healthcare.”

For media inquiries and further information, please contact:
Partex
Nidhi Duhan
Business Operations Manager
info@partex.io

About Partex:

With the power of AI at its core, the Partex Group delivers faster, lower-cost healthcare innovations, validated by wet-lab and real-world evidence. Our pioneering digital platform enables smarter decision-making throughout the entire value chain.

Partex’s pioneering digital life-science platform leverages the largest knowledge graph in the industry to impact the full pharma and healthcare value chain. Our agile teams use a flexible and scalable approach for data exchange and insight generation to enable maximally informed decision-making. To further solidify the translation of AI-generated predictions into tangible outcomes, Partex’s Contract Research Organization (CRO), Assay.Works, has the capability to conduct wet lab validation for selected indications upon client’s request. This critical step underscores the commitment to delivering safe and efficacious therapies to patients.

We deliver value to patients, clients and investors through faster, lower-cost healthcare innovations with an increased probability of success.

With a global presence that extends from Asia-Pacific to the Americas, with offices currently in India, Germany, Switzerland and the USA, Partex’s vision is to transform the Life Science Industry by solving the inefficiency problem in drug discovery & development using Big Data & Artificial Intelligence.

Partex group companies: https://www.partex.io/ https://www.innoplexus.com/ https://www.cureteq.com/ www.amrit.ai https://www.assay.works/ https://perpetualblock.io/

For more information, visit https://www.partex.io/ and follow us on LinkedIn, Twitter and Instagram.

About Althea DRF Lifesciences:

Althea DRF Lifesciences, in collaboration with its strategic partner Dabur Research Foundation (DRF), stands as an esteemed Contract Research Organization established in 1979, specializing in preclinical services vital for Drug Discovery and Development. With a rich history spanning over three decades, we offer comprehensive support ranging from lead molecule identification to IND enabling studies, catering to diverse sectors including Biotech, Pharma, Phytopharmaceuticals, Cosmeceuticals, and academia. Our expertise encompasses a wide array of functional areas such as In Vitro, Ex-Vivo & In Vivo Pharmacology, Exploratory & GLP Toxicology, and DMPK, ensuring thorough and meticulous research processes. Stemming from the esteemed Dabur group of companies, our inception as an independent preclinical service provider in 2008 marked a strategic evolution, leveraging our profound industry experience to serve clients worldwide. Althea DRF Lifesciences is dedicated to guiding and fulfilling the technical and scientific requirements of global biotech companies and pharmaceutical developers during the crucial preclinical phase of research, offering a solid foundation of laboratory services, disease models, and unparalleled expertise to drive innovation and advancement in healthcare.

For more information about Althea, visit https://www.altheadrflifesciences.com

Featured News